Tuesday May 14
Vivus Starting To Gain The Advantage Over Arena
One of the most hotly contested spaces in the biotechnology industry has been the treatment of obesity.
View Press Release
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Orexigen Therapeutics, Inc.
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
Orexigen Therapeutics, Inc. today announced that management will present a company overview at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas.
Orexigen Therapeutics, Inc. Reports Financial Results for the First Quarter Ended March 31, 2013
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! SAN DIEGO, May 8, 2013 -- /PRNewswire/ -- OrexigenA Therapeutics, Inc.
MDT, HLF, OREX, and NVS Early Briefing and Review
The Affordable Care Act , which was upheld by the Supreme Court last year, is expected to result in higher costs for the healthcare industry.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & Some Key Catalysts Approaching
The obesity stocks are perhaps some of the most discussed and followed stocks in the entire biotechnology sector.
Orexigen Therapeutics Commends the Campaign to End Obesity's...
SAN DIEGO, April 25, 2013 /PRNewswire/ -- Regarding the report "The Long Term Returns of Obesity Prevention Policies" unveiled this week by the Campaign to End Obesity , Orexigen Therapeutics, Inc.
Orexigen Therapeutics, Inc. CEO Elected to PhRMA Board of Directors
Narachi will serve as a director for a term of two years. PhRMA represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.
San Diego Source
Michael Narachi joins PhRMA's board of directors
Orexigen Therapeutics Inc. , a biopharmaceutical company focused on the treatment of obesity, announced that Michael Narachi, president and CEO, has been named to the board of directors of the Pharmaceutical Research and Manufacturers of America .